Top Page
Immuron Limited
(Sydney:IMC)
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Immuron Limited Business Overview & Revenue Model
Immuron Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.48M | 7.29M | 4.90M | 1.80M | 765.19K | 145.78K |
| Gross Profit | 4.76M | 4.77M | 3.34M | 1.31M | 523.50K | 94.70K |
| EBITDA | -5.08M | -5.31M | -6.19M | -3.80M | -3.08M | -8.33M |
| Net Income | -4.65M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
Balance Sheet | ||||||
| Total Assets | 15.14M | 10.13M | 15.55M | 21.99M | 24.86M | 27.05M |
| Cash, Cash Equivalents and Short-Term Investments | 10.00M | 5.87M | 11.66M | 18.99M | 22.11M | 25.05M |
| Total Debt | 0.00 | 117.13K | 173.50K | 189.09K | 209.79K | 20.50K |
| Total Liabilities | 2.06M | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M |
| Stockholders Equity | 13.08M | 8.07M | 12.71M | 19.62M | 23.18M | 25.90M |
Cash Flow | ||||||
| Free Cash Flow | -4.62M | -6.14M | -5.56M | -2.50M | -3.14M | -4.09M |
| Operating Cash Flow | -4.62M | -6.14M | -5.56M | -2.49M | -3.13M | -4.08M |
| Investing Cash Flow | -4.75K | -2.90M | 327.56K | -2.74M | 11.74K | 2.57K |
| Financing Cash Flow | 6.97M | 199.75K | 829.00 | -35.02K | -36.26K | 26.49M |
Immuron Limited Technical Analysis
Immuron Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$9.15M | -1.50 | -49.96% | ― | 48.63% | 25.66% | |
44 Neutral | AU$33.06M | -9.09 | -143.71% | ― | 306.88% | ― | |
43 Neutral | AU$20.28M | -3.95 | -157.93% | ― | ― | -36.89% | |
40 Underperform | AU$3.48M | -1.90 | -205.70% | ― | ― | 1.03% | |
40 Underperform | AU$34.92M | -6.91 | -16.65% | ― | ― | -672.73% | |
37 Underperform | AU$10.20M | -2.38 | -628.72% | ― | ― | 31.87% |
Immuron Limited Corporate Events
Immuron Limited has released a presentation outlining a strategic reset alongside its HY26 financial results, signaling a reassessment of its operational priorities and performance trajectory. The company notes that these FY2026 figures remain subject to audit review, underscoring that reported outcomes may still change before finalization.
Management emphasizes that its current expectations and strategic plans are inherently uncertain due to risks in developing and commercializing its technology. This caveat highlights the potential for material divergence between projected and actual results, reminding investors and stakeholders to treat the company’s forward-looking statements with caution.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited reported a 4.8% increase in revenue from ordinary activities to $4.18 million for the half-year ended 31 December 2025, while its net loss after tax narrowed by 22.9% to $1.92 million, indicating improved operating performance. The company’s net tangible asset backing declined to 3.94 cents per share from 4.46 cents a year earlier, it paid no dividends for the period, and reported no changes in its controlled entities or its 23.61% stake in U.K.-based associate Ateria Health Limited, suggesting a stable but still loss-making financial and corporate structure.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced senior leadership changes, with long-serving Chief Financial Officer and Company Secretary Phillip Hains stepping down from both roles effective 9 February 2026. The board acknowledged his contribution since 2013, marking the end of a key financial stewardship period for the biopharmaceutical group.
The company has appointed Olga Smejkalova as Company Secretary and primary contact for ASX communications, and Aaron Laurita as Chief Financial Officer, both effective immediately. These appointments bring additional governance, compliance, and commercial finance expertise to Immuron, potentially strengthening its corporate oversight as it advances its antibody-based therapies and Travelan franchise in global markets.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced that CEO Steven Lydeamore delivered a virtual presentation at the Emerging Growth Conference, highlighting the company’s orally delivered antibody platform and its portfolio of gastrointestinal-focused products. The appearance underscores Immuron’s efforts to raise its profile among growth-oriented investors as it advances its commercial product Travelan for travelers’ diarrhea, progresses IMM-529 as an adjunctive therapy for recurrent C. difficile infection with promising pre-clinical data, and expands its presence in functional gut health through the distribution of ProIBS, positioning the company as a niche player in oral immunotherapy and gastrointestinal therapeutics.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron reported unaudited global first-half sales of AUD$4.2 million, up 5% year-on-year, driven primarily by strong performance of its Travelan product in Australia and the United States, despite a sharp year-on-year decline in Canada following an earlier pipeline fill. Australian H1 sales rose 13% to AUD$3.3 million, supported by increased digital and social media marketing, expanded pharmacy ranging and higher Southeast Asian travel, while U.S. sales grew 17% to AUD$0.9 million on the back of enhanced Amazon presence and intensified social media and influencer campaigns. The company also accelerated the Australian launch of its new product ProIBS ahead of Christmas, securing distribution via two of the three largest pharmacy wholesalers and listings in five banner groups, positioning itself for further category reviews and potential shelf expansion in 2026. In Canada, although H1 sales were sharply lower versus the prior year due to timing of a large initial stock pipeline, quarterly sales rebounded 191% in Q2, and Immuron plans to further build Travelan brand awareness through in-store education, promotions and social media, with a key new rollout into Jean Coutu pharmacies in Quebec scheduled for the third quarter of FY26, which could significantly deepen its penetration in the Canadian market.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced that its Chief Executive Officer, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on 22 January 2026, with the session to be made available via live webcast and archived online for later viewing. The appearance is expected to enhance the company’s visibility among growth-focused investors and stakeholders by showcasing its targeted antibody platform and portfolio of gastrointestinal and infectious disease-focused products, potentially strengthening its positioning in the global biopharmaceutical and travel health markets.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has called an extraordinary general meeting of shareholders for 12 February 2026 in Melbourne to seek approval for the ratification of two substantial prior share issuances. Shareholders will be asked to ratify the issue of 28,278,923 shares under ASX Listing Rule 7.1 and a further 26,821,997 shares under Listing Rule 7.1A, moves that effectively regularize past capital-raising activities and restore the company’s capacity to issue additional equity in the future. The resolutions, if approved, will support Immuron’s flexibility in accessing capital markets going forward, which is significant for its ongoing funding needs and could influence future dilution, governance considerations, and the company’s ability to finance its development and commercial objectives.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the issuance of 314,843 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant provisions. This move is part of the company’s ongoing efforts to maintain transparency and adhere to regulatory requirements, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the application for quotation of 314,843 ordinary fully paid securities on the Australian Securities Exchange (ASX), with an issue date of December 16, 2025. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase its capital base, which could have implications for its operational capabilities and stakeholder interests.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has issued 1,142,909 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This issuance indicates the company’s adherence to regulatory requirements and suggests a strategic move to potentially enhance its financial position and operational capabilities.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the issuance of 1,142,909 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX) as of December 15, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase liquidity, reflecting its ongoing efforts to strengthen its financial position and operational capabilities.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced the issuance of 1,874,964 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This strategic move is part of the company’s efforts to strengthen its financial position, potentially impacting its operational capabilities and market presence.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced that the Uniformed Services University released topline results from a clinical trial evaluating a third-party manufactured product containing ETEC hyperimmune bovine colostrum. The trial did not achieve statistical significance for its primary endpoint, and the product was not administered according to Travelan® directions. As a result, Immuron does not consider these results reflective of Travelan®’s performance. The company plans to propose its established three-times-daily dosing schedule at an upcoming FDA meeting. Immuron continues to collaborate with military research institutions on vaccines and is advancing discussions for testing Travelan® against other E. coli strains.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced the quotation of 45,472,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This move is expected to enhance the company’s market presence and provide additional capital for its ongoing projects, potentially impacting its operational capabilities and stakeholder interests positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced a proposed issue of 45,472,000 ordinary fully paid securities, with the issue date set for December 5, 2025. This move is part of a placement or other type of issue, which could potentially impact the company’s market positioning by increasing its capital base and providing additional resources for its operations.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited announced a change in its share registry management services, transitioning from Automic Group to Boardroom Pty Limited effective December 8, 2025. This strategic move is expected to streamline the company’s administrative processes, potentially enhancing operational efficiency and stakeholder relations.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
Immuron Limited has announced a new research agreement funded by the U.S. Department of Defense to develop two oral therapeutics targeting Campylobacter and Shigella, in collaboration with the Naval Medical Research Command and the Walter Reed Army Institute of Research. This initiative aims to produce hyper-immune bovine colostrum products for the U.S. military, addressing the significant global burden of diarrheal diseases, which impact military readiness and global health. Additionally, Immuron is preparing to release results from a clinical trial on the effectiveness of its ETEC hyperimmune bovine colostrum in maintaining gut health during deployment and travel, highlighting its ongoing efforts to combat antibiotic-resistant enteric pathogens.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.